Shares of RadNet Inc. (NASDAQ:RDNT) reached a new 52-week high during trading on Tuesday . The company traded as high as $15.65 and last traded at $15.55, with a volume of 15009 shares traded. The stock had previously closed at $15.15.

A number of analysts recently commented on RDNT shares. BidaskClub cut shares of RadNet from a “buy” rating to a “hold” rating in a research note on Friday, June 8th. Zacks Investment Research cut shares of RadNet from a “hold” rating to a “sell” rating in a research note on Wednesday, August 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $14.75.

The company has a market capitalization of $690.47 million, a P/E ratio of 53.17, a P/E/G ratio of 5.11 and a beta of 0.22. The company has a debt-to-equity ratio of 4.49, a quick ratio of 1.06 and a current ratio of 1.06.

RadNet (NASDAQ:RDNT) last announced its quarterly earnings data on Thursday, August 9th. The medical research company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.02). RadNet had a negative net margin of 0.64% and a positive return on equity of 17.00%. The business had revenue of $244.40 million for the quarter, compared to analyst estimates of $239.34 million. During the same quarter in the previous year, the firm posted $0.11 earnings per share. The business’s revenue was up 6.3% on a year-over-year basis. research analysts expect that RadNet Inc. will post 0.35 EPS for the current year.

In other RadNet news, insider Jeffrey L. Linden sold 10,000 shares of RadNet stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $14.78, for a total transaction of $147,800.00. Following the completion of the sale, the insider now directly owns 902,001 shares in the company, valued at approximately $13,331,574.78. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 7.56% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. lifted its stake in RadNet by 17.2% during the 2nd quarter. BlackRock Inc. now owns 2,552,195 shares of the medical research company’s stock valued at $38,283,000 after acquiring an additional 374,945 shares during the period. Renaissance Technologies LLC lifted its stake in shares of RadNet by 20.7% in the 2nd quarter. Renaissance Technologies LLC now owns 2,414,812 shares of the medical research company’s stock valued at $36,222,000 after purchasing an additional 413,312 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of RadNet by 0.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,560,823 shares of the medical research company’s stock valued at $23,412,000 after purchasing an additional 10,114 shares during the period. FMR LLC acquired a new position in shares of RadNet in the 2nd quarter valued at $21,532,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of RadNet by 3.6% in the 1st quarter. JPMorgan Chase & Co. now owns 518,353 shares of the medical research company’s stock valued at $7,465,000 after purchasing an additional 17,885 shares during the period. Institutional investors and hedge funds own 60.33% of the company’s stock.

RadNet Company Profile (NASDAQ:RDNT)

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.

Further Reading: Dividend Stocks – Are They Right For You?

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.